Aims: Hypoglycaemia confers excess morbidity and mortality. UK guidelines recommend capillary blood glucose (CBG) measurement is repeated 15 minutes following identification and treatment of CBG <4 mmol/L. We assessed adherence to this guidance, influence of initial CBG on time to repeat (TTR), and the impact of a quality improvement intervention on TTR. Conclusions: TTR is a marker of treatment quality in hypoglycaemia and is suboptimal. TTR reduces with worsening initial degree of hypoglycaemia. We have shown that a quality improvement package can produce sustained reduction of TTR. Br J Diabetes Vasc Dis 2015;15:24-26 
Introduction
In hospitalised patients with diabetes, hypoglycaemia is common with a reported frequency of 3.3-5.7%. [1] [2] [3] [4] In the UK National Diabetes Inpatient Audit, hypoglycaemia occurred in 23.4% of inpatients with diabetes and 2.2% of these patients required parenteral glucose or glucagon. 5 The frequency and severity of hypoglycaemia has been associated with an increase in pre-and post-discharge mortality and length of admission. 6, 7 Even in patients without diabetes, hypoglycaemia on hospital admission has been linked with a significant increase in inpatient mortality and bed occupancy. 8 Patients experiencing hypoglycaemia (blood glucose <4 mmol/L) require prompt action with administration of rapidacting carbohydrate or glucagon followed by assessment of response to treatment by repeat blood glucose measurement. The Joint British Diabetes Societies inpatient care guidelines for the treatment of hypoglycaemia recommend that, following treatment of hypoglycaemia, CBG is repeated at between 10-15 minutes to ensure successful treatment. 9 This timescale for repeating CBG is also recommended by the American Diabetes Association for all episodes of hypoglycaemia (<70 mg/dL [3.9 mmol/L]) occurring in patients with diabetes. 10 We assessed adherence to this guidance and the influence of an intervention (National Health Service Scotland Quality Improvement Hub ThinkGlucose pilot) attempting to improve response time.
Methods
Capillary blood glucose data were extracted from the Abbott Precision Webb system (Abbott, UK In one clinical area (a 43-bed regional vascular unit in Western Infirmary Hospital Glasgow) we examined the effect of a pilot intervention (NHS Scotland Quality Improvement Hub ThinkGlucose pilot) on time to repeat CBG following hypoglycaemia. The Quality Improvement Hub is a national collaboration among health boards and Scottish Government Health Directorates which aims to support NHS boards with implementation of the Healthcare Quality Strategy, 11 while licences for Think Glucose were purchased from the NHS Institute for Innovation and Improvement. Time to repeat CBG was measured for the 14 months prior to the intervention, 12 months of the intervention and nine months following cessation of the pilot study period. The intervention involved group education of all ward staff on in-patient diabetes management, introduction of a "hypo box" with associated treatment algorithm, physical resources aimed at highlighting patients with diabetes to ward staff (magnets for white boards and stickers for charts) and a decision support tool to prompt appropriate expert review. 12 
Results
From a total of 3,345,241 CBG measurements, 90,935 (2.72%) were <4 mmol/L. Of these hypoglycaemic measurements, 4,046 (4.4%) had no recorded repeat CBG during admission and 91.8% did not meet guideline rec- 
Discussion
Our data show that, across a large grouping of teaching and district general hospitals containing a full range of secondary and tertiary care services, a concerning number of CBG in the hypoglycaemic range were never retested. When repeat testing did take place, this was not done in a timely manner in the vast majority of cases, with less than 10% of hypoglycaemic episodes being retested within the recommended 15 minutes suggested by guidelines. 9, 10 Whilst 15 minutes could be considered a very stringent and perhaps aspirational target for repeat testing, it should be noted that only 42.2% of hypoglycaemic episodes were retested by 60 minutes. In some of these cases it is possible that retesting was not done on clinical grounds such as withdrawal of active treatment and end of life care. However the fact that the initial CBG has been tested would suggest that some active treatment was considered appropriate. We note that some hypoglycaemic episodes may have been adequately treated clinically but without repeat CBG measurement. Even if this is indeed the case, this would be against recommendations and would be difficult to justify in the event of a poor clinical outcome such as a fall, seizure or death following the initial recorded low CBG.
It is likely that a number of the hypoglycaemic CBG repeat results are in the same individual patients. We do not believe that this is reassuring as, even if the hypoglycaemic CBG is a recurrence or repeat after unsuccessful treatment of hypoglycaemia, it still should be treated independently and the response to that treatment needs to be checked by again repeating CBG testing.
It is notable that in the larger data set TTR decreased with magnitude of hypoglycaemia, suggesting that ward staff recognise that lower CBG levels are potentially more harmful. 6 A larger 'step down' in response time is seen when CBG is below 3 mmol/L (54 mg/dL), indicating that whole numbers disproportionally influence the perception of severity of hypoglycaemia. We would expect that, where mg/dl units are used, such a step in response may occur at terminal digits such as between 50 and 49 mg/dL. It could be argued that CBG retesting is not meeting the target as health care staff have a justifiable perception that CBG results between 3 and 4 mmol/L are unlikely to be harmful, particularly in patients who may not be on insulin. Even if this were accepted, 2.1% of CBG results <3 mmol/L were never retested and only 17.0% were retested by 15 minutes and 61.5% by one hour, which is without doubt a concerning finding.
We have shown that a quality improvement intervention (National Health Service Scotland Quality Improvement Hub ThinkGlucose pilot) can have a measurable, pronounced and sustained impact on TTR CBG on a surgical unit. Whilst timely TTR of CBG in hypoglycaemia does not prove alone that hypoglycaemia has been adequately treated, it at least allows for assessment of success in bringing glucose into the normal range. Despite the intervention on the described unit and the subsequent sustained improvement, still only 25% of hypoglycaemia episodes are having CBG repeated within the recommended time period of 15 minutes, suggesting there is still some way to go in reaching the desired standard of care.
TTR appears to be a useful marker of quality of treatment of hypoglycaemia in in-patients and can be used as an audit measure for assessing staff training and the impact of interventions aimed at service improvement.
